Drug Profile
AUTO 4
Alternative Names: Anti-TRBC1 CAR T-cells - Autolus; AUTO-4; RQR8/aTRBC1 CAR T cells - AutolusLatest Information Update: 18 Jan 2023
Price :
$50
*
At a glance
- Originator University College London
- Developer Autolus
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II T-cell lymphoma
Most Recent Events
- 12 Dec 2022 Efficacy and safety data from a phase-I/II trial in T-cell lymphoma were released by Autolus Therapeutics
- 10 Dec 2022 Efficacy and adverse event data from the phase I/II LibrA T1 trial in T-cell lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 09 Jun 2022 Efficacy and adverse event data from the phase I/II LibrA T1 trial in T-cell lymphoma presented at the 27th Congress of the European Haematology Association (EHA-2022)